Oppenheimer Sticks to Its Buy Rating for Strongbridge Biopharma (SBBP)

In a report released yesterday, Hartaj Singh from Oppenheimer maintained a Buy rating on Strongbridge Biopharma (SBBP), with a price target of $8.00. The company’s shares closed last Wednesday at $2.49.

According to TipRanks.com, Singh is a 4-star analyst with an average return of 9.4% and a 44.1% success rate. Singh covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Alexion Pharmaceuticals, and Vertex Pharmaceuticals.

Currently, the analyst consensus on Strongbridge Biopharma is a Strong Buy with an average price target of $8.33, which is a 244.2% upside from current levels. In a report issued on October 30, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4.63 and a one-year low of $1.43. Currently, Strongbridge Biopharma has an average volume of 586.2K.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SBBP in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded on May 26, 2015 and is headquartered in Lower Southampton, PA.

Read More on SBBP:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts